Amanda J. Rode
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Pancreatic and Hepatic Oncology Research, Histone Deacetylase Inhibitors Research
Most-Cited Works
- → CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation(2017)756 cited
- → Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck(2017)88 cited
- → Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study(2021)43 cited
- → Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival(2021)28 cited
- → Effect of FAK inhibitor defactinib on tumor immune changes and tumor reductions in a phase II window of opportunity study in malignant pleural mesothelioma (MPM).(2017)10 cited
- → Knockout of CBLB Greatly Enhances Anti-Tumor Activity of CAR T Cells(2018)3 cited
- → Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study(2022)1 cited
- → Data from CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation(2023)
- → Supplementary Data from CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation(2023)